Belite Bio Completes Phase 3 DRAGON Trial for Stargardt Treatment, Share Price Rises 17%

Belite Bio has completed its Phase 3 DRAGON trial for Stargardt disease treatment, boosting investor confidence and share price by 17% over the last quarter. The successful trial and a recent private placement of $125 million have reinforced optimism around the company's prospects. Despite being considered expensive based on the Price-To-Book Ratio, Belite Bio's shares are expected to see upside if its Tinlarebant treatment materializes.

Belite Bio Inc. has announced the successful completion of the last subject visit in the Phase 3 DRAGON clinical trial evaluating Tinlarebant for the treatment of Stargardt disease type 1 (STGD1). The trial, which enrolled 104 adolescent subjects across 11 jurisdictions, has completed with 94 subjects finishing the study. The primary efficacy endpoint is the growth rate of atrophic lesions, with safety and tolerability also being assessed Belite Bio Announces Completion a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease^[1].

The completion of the DRAGON trial marks a significant milestone for Belite Bio, which is focused on advancing novel therapeutics for degenerative retinal diseases with significant unmet medical needs. The trial's success has boosted investor confidence, with Belite Bio's share price increasing by 17% over the last quarter. This positive momentum is further supported by a recent private placement of $125 million Belite Bio Completes Phase 3 Stargardt Disease Trial^[2].

Belite Bio expects to report top-line results from the DRAGON trial in Q4 2025 and plans to file New Drug Applications in the first half of 2026. Tinlarebant, the company's lead candidate, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, which are by-products of the visual cycle. The drug works by modulating the amount of retinol entering the eye, thus reducing the formation of bisretinoids Belite Bio Announces Completion a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease^[1].

The trial's completion and the recent financial activities underscore the company's strategic positioning. Belite Bio is pursuing a first-approval beachhead in STGD1 to validate its RBP4-lowering mechanism and set up label expansion into larger markets like geographic atrophy. The company's pediatric rare disease designation and various other designations, including Fast Track and Orphan Drug, create optionality on review timelines and potential incentives if efficacy is demonstrated Belite Bio Completes Phase 3 Stargardt Disease Trial^[2].

The next few months will be crucial for Belite Bio as it awaits the top-line results and regulatory interpretations. Key watch items include the magnitude of effect on lesion growth, the robustness of sensitivity analyses for missing data, safety in the adolescent population, and the company's readiness for parallel filings in the U.S., EU, and Japan. If the signal is strong, Belite Bio can leverage its pediatric rare disease designation toward a priority review voucher and use a Stargardt label to underwrite its geographic atrophy strategy. If the effect size is modest or safety introduces trade-offs, the program will face heightened regulatory scrutiny Belite Bio Completes Phase 3 Stargardt Disease Trial^[2].

Despite being considered expensive based on the Price-To-Book Ratio, Belite Bio's shares are expected to see upside if its Tinlarebant treatment materializes. Investors and financial professionals should closely monitor the upcoming data releases and regulatory decisions to assess the potential impact on the company's prospects.